Macomics Announces the Appointment of Roche Executive, Dr Valérie Méresse Naegelen, to its Clinical Advisory Panel

Edinburgh and Cambridge, UK, 12 September 2022Macomics Ltd, an immuno-oncology company with world-leading expertise in macrophage biology, is pleased to announce that Dr Valérie Méresse Naegelen, Global Head of Translational Sciences Oncology at the Pharma Division of Roche has joined its panel of Clinical Advisors.

Dr Méresse Naegelen has over 20 years of experience in research and clinical development of small and large molecule compounds for various indications in oncology. A seasoned physician scientist, she joined Roche in 2002 where she currently oversees translational and clinical activities related to the in-licensing and acquisition of external assets for Roche, pRED Oncology in Basel. Previously she gained experience in roles that encompassed both early and late clinical development of oncology assets across various technical modalities for the treatment of solid tumours and haematological diseases. Under her leadership, multiple programs have entered and progressed through clinical development, some accompanied by extensive biomarker and translational activities.

She joins eight other internationally renowned advisors from the Netherlands, France, Switzerland, the UK and Italy who bring immunology, oncology and clinical expertise to the company. These are Professor Karin de Visser, Dr Carlos Gomez-Roca, Professor Daniel Speiser, Professor Klaus Okkenhaug, Dr Mario Leonardo Squadrito, Professor Michele De Palma, Dr Jackie Doody and Dr John Haurum.

Dr Carola Ries, Macomics’ Chief Scientific Officer, said, “I am delighted that Valérie has agreed to join our clinical advisory panel. Having worked alongside her during my time at Roche, I know the depth of her expertise in oncology, both in assessing therapeutics and biomarkers, and in managing programs through early development. Her insights and experience will be invaluable as we progress our diversified portfolio of novel therapies targeting disease-specific tumour associated macrophages towards the clinic.”

Please click here to view the original press release.